Innovating antibodies, improving lives

Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.

 

financial news 260x1732018 Full Year Financial Results

Genmab published its 2018 Full Year financial results and held an investor conference call on February 20. Click here to listen to the archived webcast. Click here to download an MP3 of the call. Click here to access the full report. Click here to download a Danish Summary of the report. Click here for the online summary. Click here to download the slides from the conference call. 

 

Genmab feature_260x173Annual General Meeting 2019

Genmab's Annual General Meeting 2019 will take place Friday, March 29, 2019 at 11:00 AM CET at the Copenhagen Marriott Hotel, Copenhagen, Denmark. Please click here for more information about the Genmab's 2019 Annual General Meeting.   

 

 

Investorportal sign on_260x173InvestorPortal

To register your email address for electronic shareholder communications or to update your settings, log on to the InvestorPortal.